<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04029363</url>
  </required_header>
  <id_info>
    <org_study_id>HL-2018-01-TS Feasibility</org_study_id>
    <nct_id>NCT04029363</nct_id>
  </id_info>
  <brief_title>Feasibility Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk</brief_title>
  <official_title>Feasibility Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HighLife SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedPass International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>HighLife SAS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      to evaluate the feasibility, safety and performance of the HighLife 28mm Transcatheter Mitral
      Valve in patients with moderate-severe or severe mitral regurgitation who are at high risk
      for surgical treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2019</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device Safety</measure>
    <time_frame>30 days</time_frame>
    <description>Freedom from major adverse events</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Mitral Regurgitation</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HighLife Transcatheter Mitral Valve Replacement</intervention_name>
    <description>Transcatheter Mitral Valve Replacement</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age ≥ 18 years 2. Moderate-severe or severe mitral regurgitation (≥ 3+) 3. Patient
             has New York Heart Association (NYHA) Functional Class II, III or ambulatory IV 4.
             Patient is under guideline directed medical therapy, as reviewed and confirmed by the
             local multidisciplinary Heart Team, for at least one month 5. Patient is high-risk for
             open-heart surgery based on the assessment of the multidisciplinary Heart Team using
             standard scoring systems and consideration of co-morbidities, frailty, and disability
             6. Patient meets the anatomical criteria for HighLife valve 7. Patient is willing to
             participate in the study and provides signed informed consent

        Exclusion Criteria:

          1. Any stroke/TIA within 30 days

          2. Severe symptomatic carotid stenosis (&gt; 70% by non-invasive imaging)

          3. Active infections requiring antibiotic therapy

          4. Active ulcer or gastro-intestinal bleeding in the past 3 months

          5. History of bleeding diathesis, coagulopathy or refusal of future blood transfusion

          6. Patients in whom TEE is not feasible

          7. Patients who are pregnant or lactating, or plan to get pregnant in the next 12 months.

          8. Patient is unable to comply with the follow-up schedule and assessments

          9. Participation in another clinical investigation at the time of inclusion

         10. Patient has known allergies to the device components or contrast medium

         11. Patient cannot tolerate anticoagulation or antiplatelet therapy

         12. Patients with a life expectancy of less than 12 months due to non-cardiac conditions

         13. Patient had permanent pacemaker, or similar device with implantable cardiac leads
             (i.e. resynchronization therapy) within the last 3 months

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Martin Rothman, MD</last_name>
    <phone>+1 707 2177167</phone>
    <email>MRothman@highlifemed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Vincent's Hospital - Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Muller, MD</last_name>
      <phone>+61 2 8382 2775</phone>
      <email>dmuller@stvincents.com.au</email>
    </contact>
    <investigator>
      <last_name>David Muller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Wesley Hospital</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Worthley</last_name>
      <phone>+61 412 764 909</phone>
      <email>Sonya.McColl@genesiscare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Andrew's Hospital</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Worthley, MD</last_name>
      <phone>+61 412 764 909</phone>
      <email>Sonya.McColl@genesiscare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Warringal Hospital</name>
      <address>
        <city>Heidelberg</city>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Worthley, MD</last_name>
      <phone>+61 412 764 909</phone>
      <email>Sonya.McColl@genesiscare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Hospital</name>
      <address>
        <city>Perth</city>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Worthley, MD</last_name>
      <phone>+61 412 764 909</phone>
      <email>Sonya.McColl@genesiscare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Dubois, MD</last_name>
      <phone>+3216344235</phone>
      <email>christophe.dubois@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Christophe Dubois, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Heart Center Freiburg - Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franz-Josef Neumann, MD</last_name>
      <phone>+4976334022201</phone>
      <email>franzz-josef.neumann@universitaets-hezzentrum.de</email>
    </contact>
    <investigator>
      <last_name>Franz-Josef Neumann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Nickenig, MD</last_name>
      <phone>+4922828715217</phone>
      <email>georg.nickenig@ukbonn.de</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Richter</last_name>
      <phone>+4922828714305</phone>
      <email>jennifer.richter@ukbonn.de</email>
    </contact_backup>
    <investigator>
      <last_name>Georg Nickenig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp Lurz, MD</last_name>
      <phone>+49341865252022</phone>
      <email>philipp.lurz@helios-gesundheit.de</email>
    </contact>
    <investigator>
      <last_name>Philipp Lurz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Silesia Hospital</name>
      <address>
        <city>Katowice</city>
        <zip>40-635</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wojciech Wojakowski, MD</last_name>
      <phone>+48 604 188 669</phone>
      <email>wwojakowski@sum.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Wojciech Wojakowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lord's Transfiguration</name>
      <address>
        <city>Poznan</city>
        <zip>61-848</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Grygier, MD</last_name>
      <phone>+48 61 854 9228</phone>
      <email>marek.grygier@skpp.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Marek Grygier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Cardiology</name>
      <address>
        <city>Warsaw</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Witkowski, MD</last_name>
      <phone>+48 223 43 4127</phone>
      <email>witkowski@hbz.pl</email>
    </contact>
    <investigator>
      <last_name>Adam Witkowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 20, 2019</study_first_submitted>
  <study_first_submitted_qc>July 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

